Proshares Trust (ZBIO) Retained Earnings (2023 - 2025)
Historic Retained Earnings for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$524.7 million.
- Zenas BioPharma's Retained Earnings fell 5672.04% to -$524.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$524.7 million, marking a year-over-year decrease of 5672.04%. This contributed to the annual value of -$387.4 million for FY2024, which is 6813.63% down from last year.
- Latest data reveals that Zenas BioPharma reported Retained Earnings of -$524.7 million as of Q3 2025, which was down 5672.04% from -$473.2 million recorded in Q2 2025.
- Zenas BioPharma's Retained Earnings' 5-year high stood at -$230.4 million during Q4 2023, with a 5-year trough of -$524.7 million in Q3 2025.
- Over the past 3 years, Zenas BioPharma's median Retained Earnings value was -$404.2 million (recorded in 2024), while the average stood at -$395.2 million.
- Its Retained Earnings has fluctuated over the past 5 years, first crashed by 6813.63% in 2024, then tumbled by 5672.04% in 2025.
- Quarter analysis of 3 years shows Zenas BioPharma's Retained Earnings stood at -$230.4 million in 2023, then plummeted by 68.14% to -$387.4 million in 2024, then plummeted by 35.44% to -$524.7 million in 2025.
- Its Retained Earnings stands at -$524.7 million for Q3 2025, versus -$473.2 million for Q2 2025 and -$421.0 million for Q1 2025.